Oramed Pharmaceuticals (ORMP) Current Assets (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Current Assets came in at $68.1 million in Q1 2026, down 48.17% YoY from $131.5 million in Q1 2025, and down 48.86% on a QoQ basis from $133.3 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Current Assets (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 16 years of Current Assets data on file, last reported at $68.1 million in Q1 2026.
- Quarterly Current Assets fell 48.17% year-over-year to $68.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.1 million (down 48.17% YoY) and the FY2025 annual result came in at $133.3 million, down 6.95% from the prior year.
- Current Assets retreated to $68.1 million in Q1 2026, from $133.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $177.1 million in Q1 2024 to a low of $68.1 million in Q1 2026.
- A 5-year average of $142.6 million and a median of $143.6 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets increased 14.14% — and 2026, when it tumbled 48.17%.
- Tracing ORMP's Current Assets over 5 years: stood at $157.1 million in 2022, then gained by 3.48% to $162.6 million in 2023, then fell by 11.91% to $143.2 million in 2024, then dropped by 6.95% to $133.3 million in 2025, then slumped by 48.86% to $68.1 million in 2026.
- The last three Current Assets figures came in at $68.1 million (Q1 2026), $133.3 million (Q4 2025), and $136.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 53.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.41 Mn |
| Mar 31, 2026 | 68.15 Mn |
| Dec 31, 2025 | 133.27 Mn |
| Sep 30, 2025 | 136.12 Mn |
| Jun 30, 2025 | 99.03 Mn |
| Mar 31, 2025 | 131.48 Mn |
| Dec 31, 2024 | 143.22 Mn |
| Sep 30, 2024 | 142.77 Mn |
| Jun 30, 2024 | 153.27 Mn |
| Mar 31, 2024 | 177.10 Mn |
| Dec 31, 2023 | 162.58 Mn |
| Sep 30, 2023 | 175.71 Mn |
| Jun 30, 2023 | 150.97 Mn |
| Mar 31, 2023 | 155.16 Mn |
| Dec 31, 2022 | 157.11 Mn |
| Sep 30, 2022 | 160.17 Mn |
| Jun 30, 2022 | 134.87 Mn |
| Mar 31, 2022 | 143.56 Mn |
| Nov 30, 2021 | 152.33 Mn |
| Aug 31, 2021 | 95.34 Mn |